Metformin Hydrochloride Drug Interactions
Also known as: Metformin Hydrochloride
Metformin hydrochloride is the salt form of metformin (Glucophage), the first-line oral medication for type 2 diabetes. See the metformin monograph for complete prescribing information.Metformin Hydrochloride has 5 documented drug interactions in our database, including 0 contraindicated, 0 major, 3 moderate, and 2 minor interactions.
0
Contraindicated
0
Major
3
Moderate
2
Minor
Combining metformin and oral semaglutide can lead to an increased risk of hypoglycemia (low blood sugar) due to their additive glucose-lowering effects. Patients may experience symptoms such as dizziness, sweating, confusion, or tremor. While generally beneficial for blood sugar control, close monitoring is essential.
Mechanism
Both metformin and semaglutide work to lower blood glucose through different mechanisms. Metformin decreases hepatic glucose production and improves insulin sensitivity, while semaglutide, a GLP-1 receptor agonist, stimulates insulin secretion, suppresses glucagon secretion, and slows gastric emptying. Their combined actions can lead to a synergistic reduction in blood glucose levels.
Clinical Management
Monitor blood glucose levels more frequently, especially when initiating or titrating either medication. If hypoglycemia occurs, a dose reduction of one or both medications, particularly any concomitant insulin secretagogues (e.g., sulfonylureas) or insulin, may be necessary. Educate patients on recognizing and treating hypoglycemia.
When metformin and dulaglutide are used together, there is an increased risk of hypoglycemia due to their additive glucose-lowering effects. Patients may also experience increased gastrointestinal side effects such as nausea, vomiting, and diarrhea.
Mechanism
Both metformin and dulaglutide contribute to glucose lowering through different mechanisms (e.g., reduced hepatic glucose production, improved insulin sensitivity for metformin; increased insulin secretion, slowed gastric emptying for dulaglutide). Their combined effects can lead to an additive reduction in blood glucose.
Clinical Management
Patients should be monitored closely for signs and symptoms of hypoglycemia, especially when initiating or titrating either medication. Dose adjustments of one or both medications, particularly metformin, may be necessary to maintain glycemic control and minimize adverse effects. Advise patients on managing hypoglycemic episodes.
Combining metformin and tirzepatide can increase the risk of hypoglycemia (low blood sugar) because both medications work to lower blood glucose levels. Patients may experience symptoms such as dizziness, sweating, confusion, or shakiness.
Mechanism
Metformin primarily reduces hepatic glucose production and improves insulin sensitivity, while tirzepatide (a GIP and GLP-1 receptor agonist) enhances insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. The additive glucose-lowering effects of these two agents can lead to an increased risk of hypoglycemia.
Clinical Management
Patients should be educated on the signs and symptoms of hypoglycemia and how to manage it. Blood glucose levels should be monitored regularly, especially when starting tirzepatide or increasing its dose. Dose adjustments of metformin or other concomitant diabetes medications may be necessary to minimize hypoglycemia risk.
Metformin and liraglutide are often used together to improve glycemic control in patients with type 2 diabetes. While generally beneficial, combining these medications can increase the risk of hypoglycemia, particularly when other glucose-lowering agents are also used.
Mechanism
Both metformin and liraglutide work through different mechanisms to lower blood glucose. Metformin primarily reduces hepatic glucose production, while liraglutide enhances glucose-dependent insulin secretion and slows gastric emptying. Their additive effects on glucose lowering can lead to a greater reduction in blood sugar.
Clinical Management
Patients should be monitored for signs and symptoms of hypoglycemia, especially when initiating or titrating either medication. If hypoglycemia occurs, dose adjustments of one or both medications, or other concomitant glucose-lowering agents, may be necessary. Educate patients on recognizing and treating hypoglycemia.
When exenatide is co-administered with metformin, there is a potential for an additive effect on blood glucose lowering, which could increase the risk of hypoglycemia, although this is generally low with metformin alone. Additionally, exenatide can slow gastric emptying, which may affect the absorption rate of metformin, but typically not its overall bioavailability.
Mechanism
Exenatide is an incretin mimetic that stimulates insulin secretion in a glucose-dependent manner and suppresses glucagon, while metformin reduces hepatic glucose production and improves insulin sensitivity. Their combined glucose-lowering effects are additive. Exenatide's effect on gastric emptying can delay the absorption of orally administered drugs.
Clinical Management
This combination is commonly used and generally well-tolerated. Monitor blood glucose levels, especially when initiating exenatide or titrating doses, to identify and manage potential hypoglycemia. No specific dose adjustments for metformin are usually required, and the timing of administration is not critical for this interaction.
For complete prescribing information:
View full Metformin Hydrochloride monograph →Already managing multiple medications?
Compare prices for all your prescriptions at 67,000+ pharmacies with one free RxGo search.
Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.